I think it simply means the patient population that has been selected with CFS and ME criteria. If you look at
the 1992 book Byron Hyde edited the term ME/CFS was used in this way.
The Chief Medical Officer Report from 2002 in the UK used the term CFS/ME in a similar way. So that's before both the CCC and SEID criteria.
When it comes to deciding research criteria I think we should try to determine what's best for research, not which criteria best fits one's own illness or what makes it easier to obtain insurance reimbursement in a particular country. I don't really know if the ICC, CCC or SEID criteria are the best criteria to use in research because we have so little data and comparisons.
You speak about clarity
@Colleen Steckel but the ICC describe ME very differently than how Melvin Ramsay and the subsequent London criteria originally described it. The former requires many more symptoms than the latter while the post-exertional muscle weakness Ramsay focused on is not a requirement in the ICC. So using the term ME doesn't do away with ambiguity and lack of consensus.
EDIT: When it comes to tests, biological abnormalities or treatments described in the ICC and other documents, I and others on this forum, who try to follow research as closely as possible, think these are commonly overstated.
I don't quite understand why it's so important to you that researchers use the ICC rather than say the CCC, as many prominent researchers in the field now seem to do. Given that up to 80-90% of US patients are undiagnosed, research funding and expert clinicians are scarce and that many clinics are offering treatments like GET that could be harmful I don't see why the top priority should be the ICC versus CCC debate...